Long/short equity, biotech, healthcare, small-cap

Why PDL BioPharma Doesn't Look A Promising Long Buy

PDL BioPharma (NASDAQ:PDLI) owns a dominant intellectual property position in the humanization of monoclonal antibodies, and is monetizing this technology through royalty bearing licenses for some of the best-selling antibody drugs, such as Herceptin, Avastin, Actemra , Lucentis, Xolair, Perjeta, Kadcyla (all from Roche), and Tysabri (Biogen Idec). However, its major income-generating asset, Queen et al patents, is about to expire in December 2014. To overcome this situation, PDL BioPharma has taken $40 million debt, providing the company with 15.5% interest rate through October 2018. This deal provides an improved return on capital and will provide financial strength to support operations; still, it doesn't provide a long-term source of revenue to support operations beyond 2015. The expiration may...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details